Key Insights

Highlights

Success Rate

67% trial completion

Treatment Research

5 treatments under study, led by Trilostane

Research Leaders

7 sponsors active, led by Gynuity Health Projects

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 87/100

Termination Rate

33.3%

1 terminated out of 3 trials

Success Rate

66.7%

-19.9% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed with results

Key Signals

67% success

Data Visualizations

Phase Distribution

3Total
Not Applicable (2)
Phase 2 (1)

Trial Status

Completed2
Terminated1

Trial Success Rate

66.7%

Benchmark: 86.6%

Based on 2 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT04160221Not ApplicableCompletedPrimary

Second Trimester Medical Abortion

NCT03207880Not ApplicableCompletedPrimary

Piloting Use of Multi-Level Pregnancy Tests in Remote Abortion Services

NCT01615211Phase 2TerminatedPrimary

Randomized Study of Letrozole and Trilostane for Medical Abortion

Showing all 3 trials

Research Network

Common Treatments

  • Trilostane1
  • Letrozole1
  • 12 Hours Interval1
  • 24 Hours Interval1
  • Multilevel Pregnancy Test1

Active Sponsors

  • Gynuity Health Projects1
  • Karolinska Institutet1
  • Kristina Gemzell Danielsson1
  • Stanford University1
  • The University of Hong Kong1

Top Investigators

Activity Timeline